[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-001", "question": "A 68-year-old man presents with a 2-year history of progressive sleep dysfunction characterized by dream enactment, nocturnal stridor, and daytime somnolence. He has developed gait instability and mild cognitive decline. Polysomnography reveals non-REM parasomnias and REM sleep behavior disorder. CSF studies are normal, and brain MRI shows mild cerebellar atrophy. Which antibody is most likely associated with this syndrome?", "options": ["A) Anti-Hu antibody", "B) Anti-Yo antibody", "C) Anti-IgLON5 antibody", "D) Anti-Ma2 antibody", "E) Anti-NMDA receptor antibody"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease is a tauopathy characterized by severe sleep dysfunction (non-REM parasomnias, REM behavior disorder), bulbar symptoms, gait instability, and cognitive decline, often with normal CSF and nonspecific MRI findings. Anti-Hu and Anti-Yo are associated with limbic encephalitis and paraneoplastic cerebellar degeneration respectively. Anti-Ma2 causes diencephalic syndrome, and anti-NMDA receptor encephalitis presents with psychiatric symptoms and characteristic CSF abnormalities.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "I need to identify the antibody most likely associated with this patient's syndrome.\n\nThe key clinical features presented are:\n- Progressive sleep dysfunction (2-year history)\n- Dream enactment and REM sleep behavior disorder\n- Nocturnal stridor\n- Daytime somnolence\n- Gait instability\n- Mild cognitive decline\n- Polysomnography showing non-REM parasomnias and REM sleep behavior disorder\n- Normal CSF\n- Mild cerebellar atrophy on MRI\n\nThis clinical picture is most consistent with anti-IgLON5 disease, a relatively recently described autoimmune disorder. The hallmark features of anti-IgLON5 disease include:\n- Complex sleep disorders (both REM and non-REM parasomnias)\n- Nocturnal stridor\n- Bulbar symptoms\n- Gait abnormalities\n- Cognitive decline\n- Cerebellar ataxia\n\nAnti-Hu is typically associated with paraneoplastic encephalomyelitis and sensory neuropathy.\nAnti-Yo is associated with paraneoplastic cerebellar degeneration.\nAnti-Ma2 is associated with limbic/diencephalic/brainstem encephalitis.\nAnti-NMDA receptor antibodies cause a distinct encephalitis with psychiatric symptoms, movement disorders, and autonomic instability.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-002", "question": "A 32-year-old woman presents with irregular vaginal bleeding 18 months after an uncomplicated term delivery. Serum hCG is mildly elevated at 150 mIU/mL. Pelvic MRI demonstrates a 4 cm intrauterine mass. Endometrial biopsy reveals sheets of intermediate trophoblastic cells with eosinophilic cytoplasm, low mitotic index, and immunohistochemical staining strongly positive for hPL but negative for hCG. Which diagnosis is most likely?", "options": ["A) Choriocarcinoma", "B) Placental site trophoblastic tumor", "C) Epithelioid trophoblastic tumor", "D) Persistent hydatidiform mole", "E) Invasive mole"], "answer": "B", "answer_index": 1, "explanation": "Placental site trophoblastic tumor (PSTT) is a rare gestational trophoblastic disease derived from intermediate trophoblasts, characterized by hPL positivity and minimal hCG production. It presents months to years after pregnancy with mild hCG elevation and is relatively chemoresistant, often requiring hysterectomy. Choriocarcinoma and invasive mole have markedly elevated hCG and are hCG-positive on immunostain. Epithelioid trophoblastic tumor is even rarer and arises from chorionic-type intermediate trophoblasts.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To determine the most likely diagnosis, I'll analyze the key clinical and pathological findings:\n\nClinical presentation:\n- 32-year-old woman\n- Irregular vaginal bleeding 18 months after term delivery\n- Mildly elevated hCG (150 mIU/mL)\n- 4 cm intrauterine mass on MRI\n\nPathological findings:\n- Sheets of intermediate trophoblastic cells\n- Eosinophilic cytoplasm\n- Low mitotic index\n- Positive hPL staining\n- Negative hCG staining\n\nThese findings are most consistent with Placental Site Trophoblastic Tumor (PSTT), which:\n- Typically presents with irregular bleeding\n- Often occurs after a normal pregnancy (with variable time interval)\n- Shows only mild hCG elevation (unlike choriocarcinoma)\n- Is composed of intermediate trophoblastic cells\n- Characteristically stains positive for hPL and negative/weakly positive for hCG\n- Has a relatively low mitotic index\n\nThe other options don't match as well:\n- Choriocarcinoma: Higher hCG, higher mitotic index, different histology\n- Epithelioid trophoblastic tumor: Different histological pattern\n- Persistent/invasive hydatidiform mole: Would show chorionic villi and higher hCG\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-003", "question": "An 18-year-old male with genetically confirmed Danon disease (LAMP2 mutation) presents with severe hypertrophic cardiomyopathy (septal thickness 28 mm), ventricular pre-excitation (WPW pattern on ECG), and recurrent syncope. Electrophysiology study identifies three distinct accessory pathways. Despite maximal medical therapy, he continues to have pre-excited atrial fibrillation. What is the most appropriate next management step?", "options": ["A) Initiate flecainide therapy", "B) Perform catheter ablation of all accessory pathways", "C) Increase beta-blocker dosage", "D) Evaluate for heart transplantation", "E) Implant a dual-chamber pacemaker"], "answer": "D", "answer_index": 3, "explanation": "Danon disease causes rapidly progressive HCM, multiple accessory pathways, and skeletal myopathy with poor prognosis. Catheter ablation is often unsuccessful due to rapid pathway recurrence and progressive myocardial involvement. Beta-blockers and verapamil are contraindicated in WPW with pre-excited AF. Flecainide may transiently suppress pathways but doesn't alter disease course. Early heart transplant evaluation is recommended given the high mortality from arrhythmias and heart failure.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "To determine the most appropriate management for this 18-year-old male with Danon disease, I need to consider several factors:\n\nThe patient has:\n- Genetically confirmed Danon disease (LAMP2 mutation)\n- Severe hypertrophic cardiomyopathy (28mm septal thickness)\n- Multiple accessory pathways (WPW pattern)\n- Recurrent syncope\n- Pre-excited atrial fibrillation despite maximal medical therapy\n\nDanon disease is a rare X-linked dominant disorder characterized by cardiomyopathy, skeletal myopathy, and intellectual disability. The cardiac manifestations are often severe and progressive, with hypertrophic cardiomyopathy being common.\n\nFor the management options:\nA) Flecainide in WPW with atrial fibrillation can be dangerous as it may slow AV nodal conduction while not affecting accessory pathway conduction, potentially increasing ventricular rate.\n\nB) Catheter ablation of accessory pathways is indicated for symptomatic WPW, especially with pre-excited atrial fibrillation, to prevent sudden cardiac death.\n\nC) Increasing beta-blocker dosage is unlikely to be effective since the patient is already on \"maximal medical therapy.\"\n\nD) Heart transplantation evaluation is appropriate for end-stage cardiomyopathy in Danon disease, which typically progresses rapidly in males.\n\nE) A dual-chamber pacemaker alone would not address the dangerous accessory pathways.\n\nGiven the severity of the cardiomyopathy (28mm is extremely thick), the presence of multiple accessory pathways with pre-excited atrial fibrillation, and the underlying progressive nature of Danon disease, heart transplantation evaluation is the most appropriate next step.\n\nThe answer is (D)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-004", "question": "A 42-year-old woman with multiple sclerosis on natalizumab for 30 months develops subacute cognitive decline over 3 weeks. Her JCV antibody index is 2.8. Brain MRI reveals new non-enhancing subcortical white matter lesions without mass effect. CSF JCV PCR is positive. Which intervention is most critical to improve survival?", "options": ["A) Continue natalizumab with close monitoring", "B) Switch directly to ocrelizumab", "C) Initiate immediate plasma exchange", "D) Start mirtazapine 30 mg daily", "E) Begin mefloquine 250 mg weekly"], "answer": "C", "answer_index": 2, "explanation": "Natalizumab-associated progressive multifocal leukoencephalopathy requires immediate drug discontinuation and plasma exchange to rapidly clear the monoclonal antibody, preventing immune reconstitution inflammatory syndrome (IRIS) and improving survival. Continuing or switching immunosuppression is contraindicated. Mirtazapine and mefloquine have been investigated but lack evidence of benefit. Plasma exchange is the only intervention shown to alter mortality.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This case describes a patient with multiple sclerosis on natalizumab who has developed progressive multifocal leukoencephalopathy (PML), as evidenced by:\n- Subacute cognitive decline\n- High JCV antibody index (2.8)\n- New white matter lesions on MRI\n- Positive CSF JCV PCR\n\nPML is a serious complication of natalizumab therapy, particularly after extended treatment duration (30 months in this case). The most critical initial intervention to improve survival in PML is to remove natalizumab from the system as quickly as possible through plasma exchange (PLEX). This accelerates the clearance of natalizumab, allowing immune surveillance to return to the CNS and combat the JCV infection.\n\nContinuing natalizumab (option A) would worsen the PML by maintaining immunosuppression.\n\nDirectly switching to ocrelizumab (option B) without removing natalizumab first could potentially worsen immunosuppression.\n\nMirtazapine (option D) and mefloquine (option E) have been studied as potential adjunctive treatments for PML but have limited evidence for efficacy and are not the most critical first intervention.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-005", "question": "A 58-year-old man presents with a 5-year history of chronic urticarial rash, recurrent fevers, debilitating bone pain, and monoclonal IgM kappa on serum protein electrophoresis. Symptoms are refractory to high-dose H1/H2 antihistamines. Laboratory studies reveal markedly elevated ESR and CRP. Which cytokine is the primary therapeutic target for this condition?", "options": ["A) Interleukin-1", "B) Interleukin-6", "C) Interleukin-17", "D) Tumor necrosis factor-alpha", "E) Interferon-gamma"], "answer": "A", "answer_index": 0, "explanation": "Schnitzler syndrome is an autoinflammatory disease driven by NLRP3 inflammasome activation with overproduction of IL-1β. Anakinra, an IL-1 receptor antagonist, is first-line therapy and induces rapid remission. While IL-6 and TNF-alpha may be elevated, they are not the primary pathogenic cytokines. IL-17 and interferon-gamma are not central to the disease mechanism.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To answer this question, I need to identify the condition based on the clinical presentation and determine the primary cytokine target for treatment.\n\nThe patient presents with:\n- Chronic urticarial rash\n- Recurrent fevers\n- Debilitating bone pain\n- Monoclonal IgM kappa on serum protein electrophoresis\n- Elevated inflammatory markers (ESR, CRP)\n- Symptoms refractory to antihistamines\n\nThis clinical picture is consistent with Schnitzler syndrome, which is characterized by chronic urticaria, monoclonal IgM gammopathy, recurrent fevers, bone pain, and elevated inflammatory markers.\n\nSchnitzler syndrome is an autoinflammatory condition where interleukin-1 (IL-1) plays a central pathogenic role. The primary therapeutic target for this condition is IL-1, and IL-1 inhibitors like anakinra have shown remarkable efficacy in treating Schnitzler syndrome, often with rapid and complete resolution of symptoms.\n\nThe answer is (A)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-006", "question": "A 35-year-old man with bilateral juvenile cataracts, progressive Achilles tendon xanthomas, and cerebellar ataxia is diagnosed with cerebrotendinous xanthomatosis. Serum cholestanol level is markedly elevated. Which treatment modality has been shown to halt neurologic progression in this disorder?", "options": ["A) High-intensity statin therapy", "B) Chenodeoxycholic acid supplementation", "C) Weekly LDL apheresis", "D) Ezetimibe monotherapy", "E) Coenzyme Q10 supplementation"], "answer": "B", "answer_index": 1, "explanation": "Cerebrotendinous xanthomatosis results from CYP27A1 deficiency, causing cholestanol accumulation in neural tissue. Chenodeoxycholic acid inhibits cholesterol 7α-hydroxylase, reducing cholestanol synthesis and stabilizing neurologic function. Statins, ezetimibe, and LDL apheresis do not effectively lower central nervous system cholestanol. Coenzyme Q10 is used for mitochondrial disorders, not this condition.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to identify the most effective treatment for cerebrotendinous xanthomatosis (CTX).\n\nCerebrotendinous xanthomatosis is a rare autosomal recessive lipid storage disease caused by mutations in the CYP27A1 gene, which encodes sterol 27-hydroxylase. This enzyme deficiency leads to reduced bile acid synthesis and accumulation of cholestanol in various tissues, including the brain, tendons, and lens.\n\nLet's evaluate each treatment option:\n\nA) High-intensity statin therapy - While statins can lower cholesterol, they don't specifically address the primary defect in bile acid synthesis in CTX.\n\nB) Chenodeoxycholic acid supplementation - This is the standard treatment for CTX. Chenodeoxycholic acid (CDCA) is a primary bile acid that provides negative feedback on cholesterol 7α-hydroxylase, reducing the production of cholestanol precursors. CDCA supplementation has been shown to normalize bile acid synthesis, reduce cholestanol levels, and halt or even reverse neurological progression.\n\nC) Weekly LDL apheresis - This removes LDL from the blood but doesn't address the underlying metabolic defect in CTX.\n\nD) Ezetimibe monotherapy - While ezetimibe reduces cholesterol absorption, it's not the primary treatment for CTX.\n\nE) Coenzyme Q10 supplementation - This is not a standard treatment for CTX.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-007", "question": "A 16-year-old girl presents with cyclic, worsening right pelvic pain for 6 months, occurring with each menses. She reports normal menstrual bleeding. Pelvic ultrasound reveals a didelphic uterus with a 5 cm right hematocolpos and a normal left uterine horn. Renal ultrasound demonstrates absence of the right kidney. Which congenital anomaly best explains this presentation?", "options": ["A) Mayer-Rokitansky-Küster-Hauser syndrome", "B) OHVIRA syndrome", "C) Complete androgen insensitivity syndrome", "D) Transverse vaginal septum", "E) Imperforate hymen"], "answer": "B", "answer_index": 1, "explanation": "OHVIRA (Obstructed Hemivagina with Ipsilateral Renal Agenesis) syndrome is characterized by a didelphic uterus with obstructed hemivagina causing hematocolpos and ipsilateral renal agenesis. Patients have normal menses from the patent uterine horn. MRKH syndrome involves uterine agenesis. CAIS affects 46,XY individuals. Transverse vaginal septum and imperforate hymen occur with a normal uterus and kidneys.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to analyze the clinical presentation and imaging findings.\n\nThe patient has:\n- Cyclic pelvic pain worsening with menses\n- Normal menstrual bleeding\n- Didelphic uterus (double uterus)\n- Right hematocolpos (blood collection in the vagina)\n- Normal left uterine horn\n- Absent right kidney\n\nLet's evaluate each option:\n\nA) Mayer-Rokitansky-Küster-Hauser syndrome: Characterized by congenital absence of the uterus and upper vagina. This doesn't match our patient who has a didelphic uterus.\n\nB) OHVIRA syndrome: Obstructed Hemivagina and Ipsilateral Renal Anomaly syndrome, also known as Herlyn-Werner-Wunderlich syndrome. This involves a didelphic uterus, obstructed hemivagina, and ipsilateral renal agenesis. This perfectly matches our patient's presentation.\n\nC) Complete androgen insensitivity syndrome: Affects 46,XY individuals who appear phenotypically female due to androgen receptor defects. These patients have testes, not a uterus.\n\nD) Transverse vaginal septum: Can cause obstruction but doesn't typically present with didelphic uterus or renal anomalies.\n\nE) Imperforate hymen: Causes complete obstruction of menstrual flow, not a hemivagina, and isn't associated with uterine or renal anomalies.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-008", "question": "A 62-year-old man with a HeartMate 3 left ventricular assist device presents with acute onset of dark urine, fatigue, and dizziness. Laboratory studies demonstrate LDH 2,800 U/L and plasma free hemoglobin 80 mg/dL. Device interrogation shows increased power consumption with intermittent spikes. Transthoracic echocardiography suggests inflow cannula obstruction. What is the most appropriate immediate management?", "options": ["A) Increase warfarin target INR to 3.5-4.0", "B) Initiate intravenous unfractionated heparin infusion", "C) Administer intraventricular alteplase 25 mg", "D) Deliver intrapump alteplase 10 mg via percutaneous catheter", "E) Proceed to emergent surgical pump exchange"], "answer": "D", "answer_index": 3, "explanation": "HeartMate 3 pump thrombosis is managed with low-dose intrapump alteplase (10 mg) delivered via percutaneous catheter directly into the device, which has shown high success rates. Systemic thrombolysis or intraventricular administration risks hemorrhagic stroke. Increasing anticoagulation is insufficient for established thrombosis. Surgical exchange is reserved for thrombolysis failure or hemodynamic collapse.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "To answer this question, I need to analyze the clinical presentation and determine the most appropriate immediate management for this patient with a HeartMate 3 LVAD.\n\nThe patient presents with:\n- Dark urine, fatigue, and dizziness\n- Elevated LDH (2,800 U/L) and plasma free hemoglobin (80 mg/dL)\n- Increased power consumption with intermittent spikes on device interrogation\n- Echocardiographic evidence suggesting inflow cannula obstruction\n\nThese findings are consistent with pump thrombosis or inflow cannula obstruction in an LVAD patient. The elevated LDH and plasma free hemoglobin indicate hemolysis, which is a hallmark of pump thrombosis.\n\nFor the HeartMate 3 specifically:\n- It has a magnetically levitated impeller designed to reduce thrombosis\n- However, inflow cannula obstruction can still occur\n- When there is evidence of pump thrombosis or obstruction with hemodynamic compromise, surgical intervention is typically required\n\nLooking at the options:\nA) Increasing warfarin target would be preventative but not address the acute obstruction\nB) Heparin alone would be insufficient for an established thrombus causing obstruction\nC) Intraventricular alteplase carries significant bleeding risks and is not standard for this situation\nD) Intrapump alteplase via percutaneous catheter is not a standard approach for HeartMate 3\nE) Surgical pump exchange is indicated for confirmed pump thrombosis or obstruction with hemodynamic compromise\n\nGiven the acute presentation with evidence of significant hemolysis and device malfunction suggesting inflow cannula obstruction, the most appropriate immediate management would be surgical intervention.\n\nThe answer is (E)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-009", "question": "A 55-year-old immunocompetent gardener develops subacute onset of severe headaches, focal seizures, and left hemiparesis over 3 weeks. Brain MRI shows multiple ring-enhancing lesions with surrounding edema. CSF demonstrates lymphocytic pleocytosis (120 cells/μL) but bacterial, fungal, and mycobacterial cultures are negative. What is the most appropriate empiric therapy?", "options": ["A) Liposomal amphotericin B", "B) Albendazole plus miltefosine", "C) Vancomycin plus ceftriaxone plus dexamethasone", "D) Ganciclovir plus foscarnet", "E) Voriconazole"], "answer": "B", "answer_index": 1, "explanation": "Balamuthia mandrillaris, a free-living amoeba, causes granulomatous encephalitis in immunocompetent individuals with soil exposure, presenting as ring-enhancing lesions mimicking brain abscess or tuberculosis. The combination of albendazole and miltefosine is the recommended treatment. Amphotericin B is used for Acanthamoeba, while voriconazole treats fungal infections. The antiviral combination is for CMV encephalitis.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to analyze the clinical presentation and diagnostic findings.\n\nThe patient is:\n- 55-year-old immunocompetent gardener\n- Presenting with subacute onset (3 weeks) of severe headaches, focal seizures, and left hemiparesis\n- MRI shows multiple ring-enhancing lesions with surrounding edema\n- CSF shows lymphocytic pleocytosis (120 cells/μL)\n- Negative bacterial, fungal, and mycobacterial cultures\n\nThe clinical picture suggests a CNS infection. Given the patient is a gardener (soil exposure), immunocompetent, has a subacute presentation, ring-enhancing lesions, and lymphocytic pleocytosis with negative routine cultures, this is highly suspicious for free-living amoeba infection, particularly Acanthamoeba or Balamuthia mandrillaris.\n\nFor these infections, the recommended empiric therapy would be a combination of albendazole (antiparasitic) and miltefosine, which has shown efficacy against free-living amoebae.\n\nThe other options are less appropriate:\n- Amphotericin B: Used for fungal infections, but cultures were negative\n- Vancomycin/ceftriaxone/dexamethasone: For bacterial meningitis, but presentation is subacute\n- Ganciclovir/foscarnet: For viral encephalitis (typically CMV), but not fitting this presentation\n- Voriconazole: For fungal infections, but cultures were negative\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-010", "question": "An 8-year-old boy presents with recurrent fevers, livedo racemosa, recurrent lacunar strokes, and vasculitic neuropathy. Laboratory studies show low IgM, elevated IgA, and negative ANCA. Genetic testing confirms biallelic loss-of-function mutations in ADA2. Which biologic therapy is most effective for this condition?", "options": ["A) High-dose systemic glucocorticoids", "B) Intravenous cyclophosphamide", "C) Etanercept", "D) Anakinra", "E) Rituximab"], "answer": "C", "answer_index": 2, "explanation": "DADA2 (Deficiency of Adenosine Deaminase 2) causes vasculitis due to loss of ADA2 enzyme function, leading to macrophage polarization defects and TNF-alpha overproduction. Etanercept, a TNF-alpha inhibitor, is highly effective and can induce remission. Cyclophosphamide and steroids are less effective. Anakinra has variable response, and rituximab is ineffective as the disease is not B-cell mediated.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This case describes a child with deficiency of adenosine deaminase 2 (DADA2), a rare autoinflammatory disease characterized by:\n- Recurrent fevers\n- Livedo racemosa (net-like skin discoloration)\n- Recurrent lacunar strokes\n- Vasculitic neuropathy\n- Immunoglobulin abnormalities\n- Confirmed by genetic testing showing biallelic mutations in ADA2\n\nDADA2 causes a vasculopathy that primarily affects small and medium-sized vessels. While several immunosuppressive therapies have been tried, anti-TNF agents have shown the most consistent efficacy in controlling the disease and preventing strokes.\n\nAmong the options:\n- Etanercept is a TNF inhibitor that has demonstrated excellent efficacy in DADA2\n- Glucocorticoids and cyclophosphamide have limited efficacy\n- Anakinra (IL-1 inhibitor) is not specifically effective for DADA2\n- Rituximab (anti-CD20) targets B cells but is not a first-line therapy for this condition\n\nThe answer is (C)"}]